Promise of Bispecific Antibodies in MM

Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains the promise of bispecific antibodies in multiple myeloma (MM) treatment for patients. Author: obr Added: 07/01/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts